# EDGAR Filing Document

**Accession Number:** 0001500198
**File Stem:** 0001213900-25-123881
**Filing Date:** 2025-12
**Character Count:** 16627
**Document Hash:** f43ed03896283067040b703b32ae56bb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-25-123881.hdr.sgml**: 20251219

**ACCESSION NUMBER**: 0001213900-25-123881

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20251219

**DATE AS OF CHANGE**: 20251219

**EFFECTIVENESS DATE**: 20251219

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** NEUROONE MEDICAL TECHNOLOGIES Corp
- **CENTRAL INDEX KEY:** 0001500198
- **STANDARD INDUSTRIAL CLASSIFICATION:** SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 270863354
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0930

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-292295
- **FILM NUMBER:** 251587972

**BUSINESS ADDRESS:**
- **STREET 1:** 7599 ANAGRAM DR
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344
- **BUSINESS PHONE:** (952) 426-1383

**MAIL ADDRESS:**
- **STREET 1:** 7599 ANAGRAM DR
- **CITY:** EDEN PRAIRIE
- **STATE:** MN
- **ZIP:** 55344

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Original Source Entertainment, Inc.
- **DATE OF NAME CHANGE:** 20100830

**As filed with the Securities and Exchange Commission on December 19, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM S-8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

**NeuroOne Medical Technologies Corporation**

(Exact name of registrant as specified in its charter)

---

| | |
|:---|:---|
| **Delaware** | **27-0863354** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification Number.) |

---

---

| | |
|:---|:---|
| **7599 Anagram Dr., <br> Eden Prairie, MN** | **55344** |
| (Address of principal executive offices) | (Zip code) |

---

**NeuroOne Medical Technologies Corporation 2021 Inducement Plan**

(Full title of the plan)

**David Rosa**

**President and Chief Executive Officer**

**NeuroOne Medical Technologies Corporation**

**7599 Anagram Dr.,<br> Eden Prairie, MN 55344**

**952-426-1383**

(Name, address, and telephone number, including area code, of agent for service)

**Copy to:**

**Phillip D. Torrence, Esq.**

**Jeffrey Kuras, Esq.**

**Honigman LLP**

**650 Trade Centre Way, Suite 200**

**Kalamazoo, Michigan 49002-0402**

**(269) 337-7700**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

**EXPLANATORY NOTE**

This Registration Statement on Form S-8 is being filed by NeuroOne Medical Technologies Corporation, a Delaware corporation. (the "***Company***" or "***Registrant***") for the purpose of registering an additional 575,000 shares of the Registrant's common stock, $0.001 par value (the "***Common Stock***") issuable pursuant to the Registrant's 2021 Inducement Plan (the "***Inducement Plan***").

Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed for the purpose of increasing the number of securities of the same class as other securities for which a Registration Statement of the Company on Form S-8 relating to the Inducement Plan is effective, and the Company's Registration Statements on Form S-8 previously filed with the Securities and Exchange Commission (the "Commission") on December 15, 2023 (File No. 333-276079) and November 23, 2021 (File No. 333-261302) registering shares of Common Stock issuable under the Inducement Plan are incorporated by reference in this Registration Statement.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference.

The following documents filed with the Commission by the Registrant are hereby incorporated by reference in this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) our
Annual Report on [Form 10-K](http://www.sec.gov/Archives/edgar/data/1500198/000121390025122390/ea0268749-10k_neuroone.htm) for the year ended September 30, 2025 filed with the Commission on December 17, 2025;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) our
Current Reports on Form 8-K filed with the Commission on [October 6, 2025](http://www.sec.gov/Archives/edgar/data/1500198/000121390025096548/ea0260404-8k_neuroone.htm) and [November 5, 2025](http://www.sec.gov/Archives/edgar/data/1500198/000121390025106454/ea0263939-8k_neuroone.htm) ;
and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the
description of our Common Stock in our registration statement on [Form 8-A](http://www.sec.gov/Archives/edgar/data/1500198/000121390021028934/ea141508-8a12b_neuroone.htm) filed with the SEC on May 25, 2021 and as amended by any subsequent amendment or report filed
for the purpose of updating such description.

In addition, all documents the Registrant subsequently files pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended, after the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities covered hereby then remaining unsold are incorporated by reference in this Registration Statement and are a part hereof from the date of filing of such documents. Notwithstanding anything herein, the Registrant is not incorporating by reference any information furnished under Item 2.02 or Item 7.01 of any Current Report on Form 8-K, unless, and to the extent, specified in any such Current Report on Form 8-K.

Any statement herein or contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein, or in any subsequently filed document, which also is or is deemed to be incorporated by reference herein, modifies or supersedes such prior statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute part of this Registration Statement.

**Item 8. Exhibits.**

**EXHIBIT INDEX**

The following exhibits are filed as part of this Registration Statement.

**INDEX TO EXHIBITS**

---

| | |
|:---|:---|
| **Exhibit<br> Number** | **Description** |
| 4.1 | [Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.4 on the Registrant's Current Report on Form 8-K filed on June 29, 2017)](http://www.sec.gov/Archives/edgar/data/1500198/000114420417034948/v470040_ex3-4.htm) |
| 4.2 | [Certificate of Amendment to Amended and Restated Certificate of Incorporation of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant's Current Report on Form 8-K filed on March 31, 2021)](http://www.sec.gov/Archives/edgar/data/1500198/000121390021018989/ea138690ex3-1_neuroone.htm) |
| 4.3 | [Amended and Restated Bylaws of NeuroOne Medical Technologies Corporation (incorporated by reference to Exhibit 3.1 on the Registrant's Current Report on Form 8-K filed on June 21, 2024)](https://www.sec.gov/Archives/edgar/data/1500198/000121390024054782/ea020821701ex3-1_neuro.htm) |
| 4.4 | [NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 on the Registrant's Current Report on Form 8-K filed on October 4, 2021)](http://www.sec.gov/Archives/edgar/data/1500198/000101376221000094/ea148325ex10-1_neuroone.htm) |
| 4.5 | [First Amendment to NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.2 on the Registrant's Current Report on Form 8-K filed on November 14, 2023)](http://www.sec.gov/Archives/edgar/data/1500198/000121390023087126/ea188259ex10-2_neuroone.htm) |
| 4.6 | [Second Amendment to NeuroOne Medical Technologies Corporation 2021 Inducement Plan (incorporated by reference to Exhibit 10.1 on the Registrant's Quarterly Report on Form 10-Q filed on August 14, 2025)](https://www.sec.gov/Archives/edgar/data/1500198/000121390025076080/ea025154601ex10-1_neuro.htm) |
| 5.1 | [Opinion of Honigman LLP](ea027011201ex5-1_neuroone.htm) |
| 23.1 | [Consent of Baker Tilly US, LLP](ea027011201ex23-1_neuroone.htm) |
| 23.2 | [Consent of Honigman LLP (included in its opinion filed as Exhibit 5.1 to this Registration Statement)](ea027011201ex5-1_neuroone.htm) |
| 24.1 | [Power of Attorney (included after the signature of the Registrant contained on Signature Page of this Registration Statement)](#poa) |
| 107 | [Filing Fee Table](ea027011201ex-fee_neuroone.htm) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Eden Prairie, State of Minnesota, on December 19, 2025.

---

| | |
|:---|:---|
| **NeuroOne Medical Technologies Corporation** | **NeuroOne Medical Technologies Corporation** |
| By: | /s/ David Rosa |
|  | David Rosa |
|  | *President and Chief Executive Officer* |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints David Rosa and Ronald McClurg, or either of them, as his or her true and lawful attorneys-in-fact and agents, with the full power of substitution and resubstitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments to this Registration Statement (including post-effective amendments), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ David Rosa | President and Chief Executive Officer | December 19, 2025 |
| David Rosa | (Principal Executive Officer) and a Director |  |
| /s/ Ronald McClurg | Chief Financial Officer (Principal Financial Officer and | December 19, 2025 |
| Ronald McClurg | Principal Accounting Officer) |  |
| /s/ Paul Buckman | Director | December 19, 2025 |
| Paul Buckman |  |  |
| /s/ Jeffrey Mathiesen | Director | December 19, 2025 |
| Jeffrey Mathiesen |  |  |
| /s/ Edward Andrle | Director | December 19, 2025 |
| Edward Andrle |  |  |
| /s/ Jason Mills | Director | December 19, 2025 |
| Jason Mills |  |  |

---

## Exhibit 5.1

**Exhibit 5.1**

![](ex5-1_001.jpg)

December 19, 2025

NeuroOne Medical Technologies Corporation<br> 7599 Anagram Drive <br> Eden Prairie, MN 55344

---

| | |
|:---|:---|
| ***Re:*** | ***Registration Statement on Form S-8*** |

---

Ladies and Gentlemen:

We have acted as counsel to NeuroOne Medical Technologies Corporation, a Delaware corporation (the "***Company***"), in connection with the preparation and filing with the Securities and Exchange Commission (the "***Commission***") of a Registration Statement on Form S-8 (the "***Registration Statement***") for the registration under the Securities Act of 1933, as amended (the "***Securities Act***"), of a maximum of 575,000 shares of the Company's common stock, par value $0.001 per share (the "***Common Stock***"), to be issued pursuant to awards under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan (the "***Plan***").

Based upon our examination of such documents and other matters as we deem relevant, we are of the opinion that the shares of Common Stock to be offered by the Company under the Plan pursuant to the Registration Statement are duly authorized and, when issued and sold by the Company in accordance with the Plan and the awards thereunder, the Registration Statement and the related prospectus, will be validly issued, fully paid and non-assessable.

We hereby consent to the filing of this opinion with the Commission as Exhibit 5.1 to the Registration Statement. In giving such consent, we do not admit that we are within the category of persons whose consent is required by Section 7 of the Securities Act or the rules and regulations promulgated thereunder by the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Honigman LLP |
| HONIGMAN LLP |

---

PDT/JVK/SEME/JPK

**Honigman LLP • 650 Trade Centre Way • Suite 200 • Kalamazoo, Michigan 49002-0402**

## Exhibit 23.1

**Exhibit 23.1**

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in the Registration Statement on Form S-8 of NeuroOne Medical Technologies Corporation (the "Company") of our report dated December 17, 2025, relating to the financial statements of the Company, which report expresses an unqualified opinion on the financial statements for the year ended September 30, 2025 and includes an explanatory paragraph relating to substantial doubt about the Company's ability to continue as a going concern as described in Note 2 to the financial statements, appearing in the Annual Report on Form 10-K for the year ended September 30, 2025.

/s/ Baker Tilly US, LLP

Minneapolis, Minnesota

December 19, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? Filing Fee Exhibit

**Ex-Filing Fees**

**CALCULATION OF FILING FEE TABLES**

**S-8**

**NeuroOne Medical Technologies Corporation**

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Security Class Title** | **Notes** | **Fee Calculation<br> Rule** | **Amount Registered** | **Proposed Maximum Offering<br> Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Equity | Common stock, par value $0.001 per share, to be issued under the NeuroOne Medical Technologies Corporation 2021 Inducement Plan | (1) | Other | 575000 | $0.6110 | $351325.00 | 0.0001381 | $48.52 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | $351325.00 |  | 48.52 |
| Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: | Total Fee Offsets: |  |  | 0.00 |
| Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: | Net Fee Due: |  |  | $48.52 |

---

**__________________________________________ Offering Note(s)**

&nbsp;&nbsp;&nbsp;&nbsp;(1) In addition, pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement also covers an indeterminate number of additional shares of Common Stock which may be offered and issued to prevent dilution resulting from stock splits, stock distributions or similar transactions. Estimated solely for the purpose of calculating the registration fee pursuant to paragraph (h) of Rule 457 under the Securities Act. The proposed maximum offering price per share is based upon the exercise price for the shares of common stock underlying outstanding stock options pursuant to Rule 457(h) under the Securities Act.